Isaura Santos,  —

Pluristem Therapeutics was recently granted an Australian patent entitled “Adherent Cells From Placenta Tissue and Use Thereof in Therapy,” and was assigned patent number 2009288781 covering Pluristem’s proprietary 3D method to grow cells from both placental or adipose tissue that can be used as treatment for several conditions including pulmonary hypertension. The term of the patent…

The Pulmonary Hypertension Association (PHA), the US’s leading fundraising and advocacy group for funding scientific research to discover new ways to prevent and cure pulmonary hypertension (PH), will celebrate its 25th Anniversary in 2016. In celebration of that milestone and to continue the fight against the disease, the PHA has announced that…

Bellerophon Therapeutics, Inc., a clinical-stage biotherapeutics company, recently announced the formation of a Scientific Advisory Board (SAB) for its INOpulse technology that includes internationally recognized experts in the field of pulmonary hypertension (PH). The SAB will work closely with Bellerophon’s medical team while the firm prepares to further the advancement of its proprietary inhaled…

Serodus ASA recently announced that the company has filed a provisional patent application with the United Kingdom patent office for its experimental SER100 therapy, which will begin development for treatment of Pulmonary Hypertension. “We are pleased to introduce a new indication for one of our drug candidates. SER100 will now also be…

April has been named the month for highlighting the importance of organ donation for those living with pulmonary hypertension (PH). The Pulmonary Hypertension Association (PHA) is celebrating Donate Life Month to encourage people to become organ donors and be aware of the need for early screening, diagnosis, and treatment of the disease. The PHA depends on…

The Pulmonary Hypertension Association (PHA), for the 12th consecutive year, has received a 4-star rating from Charity Navigator — the premier evaluator of charities in the United States. This premium designation indicates that PHA adheres to sound fiscal management, good governance, transparency, commitment to accountability and other best practices,…

Actelion recently announced that it has received marketing approval for Opsumit®, the trade name for macitentan, as a treatment for pulmonary arterial hypertension (PAH) from Japan’s Ministry of Health Labor and Welfare. This approval was supported by data collected from a local assessment conducted in Japan and data from the SERAPHIN study, a…

Giving a Voice to Pulmonary Hypertension: First Entertainment Credit Union Features #PHAware Advocates Steve and Lucas Van Wormer (PRNewsFoto/First Entertainment Credit Union) Lucas Van Wormer, a thirteen-year-old voice actor with PH working at Cartoon Network, along with his father, partnered with a credit union to raise awareness for pulmonary…

Albuquerque-based Respira Therapeutics, Inc. is a biopharmaceutical company currently developing a dry powder inhaler drug delivery technology called AOS-DPI for RT234, a drug that is being designed to address pulmonary hypertension and other respiratory diseases such as IPF and COPD. In an effort to bolster the company’s commercialization efforts, they recently announced that Andy Clark has been appointed…

The ERS Pulmonary Hypertension Research Award will grant €40,000 to a pair of carefully selected scientists currently pursuing active research projects in the field of pulmonary hypertension, with regard to its pathophysiology, basic science, epidemiology, clinical practice, prevention, treatment, diagnosis or rehabilitation. The awards are reserved exclusively for candidates younger than 45 years old at the time…

SteadyMed Ltd., an Israel-based pharmaceutical company developing and commercializing therapeutic candidates to address the limitations of top market products in treating orphan diseases, recently announced that it raised $12.2 million in equity financing to fund its PAH drug development efforts. The financing round was led by subsidiaries of Deerfield Management Company…

Thanks to a partnership with IntelGenx Corp (IGXT), Pacific Therapeutics Ltd. is combining two approved drugs to create a once per day tablet to treat pulmonary fibrosis and other diseases that result from excess scarring. Pacific Therapeutics is a clinical stage Specialty Pharmaceutical Company that reformulates and reappropriates FDA approved drugs…